MedPath

MESS-study MRSA Eradication Study Skåne

Not Applicable
Completed
Conditions
Throatcarriers of MRSA
Interventions
Drug: Rifampin+Clindamycine or Trimehoprimsulfa
Registration Number
NCT01269541
Lead Sponsor
Region Skane
Brief Summary

The purpose of this study is to determine whether systemic antibiotic treatment with rifampicin and clindamycine or trimethoprim-sulfa in addition to topical treatment with mupirocin is more effective than only topical treatment to eradicate MRSA in throatcarriers

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
69
Inclusion Criteria

Colonized with MRSA in the throat Older than 5 years MRSA-bacteria sensitive for Rifampicin and Clindamycine or Trimethoprimsulfa -

Exclusion Criteria

Allergy to the studymedication Healthcareworkers Pregnancy Active infection with MRSA Immunosuppression Treatment with other antibiotic during the studyperiod

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
MupirocinRifampin+Clindamycine or TrimehoprimsulfaTopical treatment
Rifampicin+Clindamycine or TrimethoprimsulfaRifampin+Clindamycine or TrimehoprimsulfaRifampicin 10 mg/kgx1xVII Clindamycine 300 mgx3xVII Trimethoprimsulfa 400mg/80mg 2x2
MupirocinMupirocinTopical treatment
Primary Outcome Measures
NameTimeMethod
Culture for MRSAafter 6 months
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (6)

Kristianstad hospital

🇸🇪

Kristianstad, Skåne, Sweden

Örebro university hospital

🇸🇪

Örebro, Sweden

SUS Malmö

🇸🇪

Malmö, Skåne, Sweden

Helsingborg hospital

🇸🇪

Helsingborg, Skåne, Sweden

Karolinska university hospital

🇸🇪

Stockholm, Sweden

Infectious department SUS Lund

🇸🇪

Lund, Skåne, Sweden

© Copyright 2025. All Rights Reserved by MedPath